Pay in 4 interest-free payments of $6.66 Learn more
Ships within 48 hours · Estimated delivery Aug 8 - Aug 13
You can then continue with your next injection on your usual treatment day, even if there are only a few days between doses
November 2025: FDA approved expanded Zepbound (tirzepatide) indication for moderate-to-severe obstructive sleep apnea in adults with obesity, following SURMOUNT-OSA trial data showing 62.8% reduction in apnea-hypopnea index the first drug approval for sleep apnea treatment
Starting Weight: Individuals with a higher starting weight often see faster initial progress because their bodies require more energy to function
We have to be cautious
We dont step away after a procedure or prescription, we remain your partner throughout the journey
Screening and data extraction After removing duplicate studies from the initial search results, two authors independently screened the titles and abstracts to exclude irrelevant articles
